3HP 2827
Alternative Names: 3HP-2827Latest Information Update: 25 Apr 2024
At a glance
- Originator 3H Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Apr 2024 3H Pharmaceuticals plans a phase I/II trial for Solid tumors (Unresectable/Inoperable, Metastatic disease, Late-stage disease) in China (PO) in June 2024 (NCT06378593)
- 14 Mar 2024 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the American Association for Cancer Research, 2024 (AACR-2024)
- 07 Mar 2024 Preclinical trials in Solid tumours in China (PO) (3H Pharmaceuticals pipeline, March 2024)